RESUMO
BACKGROUND: In recent years, the incidence of gynecomastia in adult men has increased significantly. It is of interest to study the specific features of the disease in these patients. AIM: To identify the main characteristics of acute gynecomastia in adult men. MATERIALS AND METHODS: A continuous one-stage study including 160 adult males with acute onset gynecomastia, who were he was treated in Endocrinology Research Centre, Moscow. Total bilirubin, hepatic transaminases, creatinine, urea, luteinizing hormone, prolactin, sex hormone binding globulin, estradiol, total testosterone, alpha-fetoprotein, chorionic gonadotropin and mammary gland condition were evaluated in all patients. Baseline significance threshold level of p<0.05. RESULTS: The incidence of gynecomastia increased from 5,4% in 2020 to 14,4% in 2024. Tumor forms of gynecomastia were rare, with 1,2% (95% CI 0,0; 3,0) of cases. In 30% (95% CI 22,9; 37,1) of men, gynecomastia was due to the intake of anabolic steroids for athletic stimulation. In 11,2% (95% CI 6,4; 16,1) of patients, gynecomastia was hepatogenic. In 7,5% (95% CI 3,4; 11,6), it was due to elevated sex hormone binding globulin. 47,5% (95% CI 39,8; 55,2) were endocrine non-tumorigenic form of gynecomastia due to excess body weight with formation of changes in sex hormone levels. The patients who took anabolic steroids were characterized by young age, as well as decreased luteinizing hormone levels and increased testosterone levels. The group of patients with elevated sex hormone binding globulin had no clinically significant features. Men from the group of hepatogenic gynecomastia were characterized by hyperestrogenism. Patients in the group with altered sex hormone levels were characterized by high body mass index and either increased estradiol or decreased testosterone or a combination of both. CONCLUSION: The number of adult male patients with acute gynecomastia is progressively increasing. In the examined sample of patients, the main causes of gynecomastia were patients taking anabolic steroids, liver dysfunction and weight gain with the formation of changes in sex hormone levels. Patients taking anabolic steroids were characterized by a drug--induced increase in testosterone and estradiol levels, which was accompanied by suppression of pituitary gonadotropic function. Estradiol elevation was also characteristic of patients with hepatogenic form of gynecomastia and men with excess body weight with formation of changes in sex hormone levels.
Assuntos
Ginecomastia , Humanos , Ginecomastia/sangue , Ginecomastia/epidemiologia , Masculino , Adulto , Pessoa de Meia-Idade , Testosterona/sangue , IncidênciaRESUMO
OBJECTIVE: To present a case of bilateral gynecomastia in a prepubertal boy with autism spectrum disorder, diagnosed with myotonic dystrophy type 1. CASE DESCRIPTION: A 12-year-old boy with autism spectrum disorder presented at a follow-up visit with bilateral breast growth. There was a family history of gynecomastia, cataracts at a young age, puberty delay, and myotonic dystrophy type 1. The physical examination showed that he had bilateral gynecomastia with external genitalia Tanner stage 1. Neurologic examination was regular, without demonstrable myotonia. The analytical study revealed increased estradiol levels and estradiol/testosterone ratio. After excluding endocrine diseases, the molecular study of the dystrophia myotonica protein kinase gene confirmed the diagnosis of myotonic dystrophy type 1. COMMENTS: A diagnosis of prepubertal gynecomastia should include an investigation for possible underlying diseases. This case report highlights the importance of considering the diagnosis of myotonic dystrophy type 1 in the presence of endocrine and neurodevelopmental manifestations.
Assuntos
Ginecomastia/etiologia , Distrofia Miotônica/complicações , Transtorno do Espectro Autista/complicações , Criança , Estradiol/sangue , Genitália Masculina/anatomia & histologia , Ginecomastia/sangue , Humanos , Masculino , Distrofia Miotônica/sangue , Distrofia Miotônica/diagnóstico , Distrofia Miotônica/genética , Miotonina Proteína Quinase/genética , Linhagem , Puberdade , Testosterona/sangueRESUMO
ABSTRACT Objective: To present a case of bilateral gynecomastia in a prepubertal boy with autism spectrum disorder, diagnosed with myotonic dystrophy type 1. Case description: A 12-year-old boy with autism spectrum disorder presented at a follow-up visit with bilateral breast growth. There was a family history of gynecomastia, cataracts at a young age, puberty delay, and myotonic dystrophy type 1. The physical examination showed that he had bilateral gynecomastia with external genitalia Tanner stage 1. Neurologic examination was regular, without demonstrable myotonia. The analytical study revealed increased estradiol levels and estradiol/testosterone ratio. After excluding endocrine diseases, the molecular study of the dystrophia myotonica protein kinase gene confirmed the diagnosis of myotonic dystrophy type 1. Comments: A diagnosis of prepubertal gynecomastia should include an investigation for possible underlying diseases. This case report highlights the importance of considering the diagnosis of myotonic dystrophy type 1 in the presence of endocrine and neurodevelopmental manifestations.
RESUMO Objetivo: Apresentar o caso de um adolescente pré-púbere com ginecomastia bilateral e transtorno do espectro autista, diagnosticado com distrofia miotônica tipo 1. Descrição do caso: Adolescente do sexo masculino de 12 anos, com transtorno do espectro autista, observado em consulta de seguimento por crescimento mamário bilateral. O paciente tinha antecedentes familiares de ginecomastia, catarata em idade jovem, atraso pubertário e distrofia miotônica tipo 1. À observação física, apresentava ginecomastia bilateral estádio 1 de Tanner. O exame neurológico era normal, sem miotonia aparente. O estudo analítico mostrou níveis elevados de estradiol e da relação estradiol/testosterona. Após exclusão de causas endócrinas, o estudo molecular do gene DMPK confirmou o diagnóstico de distrofia miotônica tipo 1. Comentários: Perante um quadro de ginecomastia pré-púbere, deve-se excluir doenças subjacentes. Este caso reforça a importância de considerar o diagnóstico de distrofia miotônica tipo 1 na presença de manifestações endócrinas e do neurodesenvolvimento.
Assuntos
Humanos , Masculino , Criança , Ginecomastia/etiologia , Distrofia Miotônica/complicações , Linhagem , Testosterona/sangue , Puberdade , Estradiol/química , Miotonina Proteína Quinase/genética , Transtorno do Espectro Autista , Genitália Masculina/anatomia & histologia , Ginecomastia/sangue , Distrofia Miotônica/diagnóstico , Distrofia Miotônica/genética , Distrofia Miotônica/sangueRESUMO
Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. However, the use of dopamine (DA) antagonists may lead to hyperprolactinemia under certain clinical conditions. The aim of this study was to investigate postmortem PRL levels as potential markers of drug abuse, especially that of DA antagonists, in autopsy cases. We examined 121 autopsy cases, excluding cases involving acute hypoxia/ischemia, such as asphyxia, because PRL concentrations are reportedly increased under acute hypoxic conditions. Detected drugs were classified as either DA antagonists, stimulants, psychotropic drugs other than DA antagonists, or other non-psychotropic drugs, and many cases had no detected drugs. Samples comprised blood collected from the right heart chamber and cerebrospinal fluid (CSF). PRL protein level was measured by chemiluminescent immunoassay, and PRL gene expression in the anterior pituitary of autopsy cases was analyzed by reverse transcription-polymerase chain reaction. The PRL-positive cell ratio in the anterior pituitary gland was also measured by immunohistochemical analysis. The results indicated that PRL levels in the serum and CSF were higher in DA antagonist cases than in other cases. PRL levels in the serum and CSF also correlated with the PRL gene expression in cases with abuse of DA antagonists. However, no significant difference in the PRL-positive cell ratio in the anterior pituitary gland was evident between any of the classes of drug-detected and drug-undetected cases. These results suggest that postmortem measurements of PRL transcription levels may be useful for diagnosing cases of DA antagonist use.
Assuntos
Antagonistas de Dopamina , Prolactina/genética , Transtornos Relacionados ao Uso de Substâncias/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Autopsia , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Criança , Pré-Escolar , Dopamina/sangue , Feminino , Expressão Gênica , Ginecomastia/sangue , Ginecomastia/líquido cefalorraquidiano , Ginecomastia/diagnóstico por imagem , Ginecomastia/genética , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Miocárdio/metabolismo , Prolactina/sangue , Prolactina/líquido cefalorraquidiano , Psicotrópicos , RNA Mensageiro/metabolismo , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/líquido cefalorraquidiano , Adulto JovemRESUMO
Gear M. You're the flight surgeon: pituitary adenoma. Aerosp Med Hum Perform. 2019; 90(8):740-743.
Assuntos
Medicina Aeroespacial , Ginecomastia/diagnóstico , Prolactinoma/diagnóstico , Adulto , Ginecomastia/sangue , Ginecomastia/etiologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Militares , Hipófise/diagnóstico por imagem , Prolactina/sangue , Prolactinoma/sangue , Prolactinoma/complicaçõesRESUMO
Objective: Gynecomastia is defined as a benign proliferation of male breast glandular tissue. Its prevalence during puberty varies between 50-60% and is also common in neonatal and elderly males. It develops mainly due to the disequilibrium between estrogen and androgen activity in breast tissue, where estradiol (E2) binds to estrogen receptors and stimulates ductal and glandular cells. The aim of this work was to investigate the relationship between sex hormone alterations and the natural history of gynecomastia. Methods: Participants in this study were young males referred to an outpatient clinic, between January 2011 and February 2016, with breast enlargement. Thyroid function, liver function, hormone concentrations and tumor markers were measured and anthropometric assessment was conducted. Results: Subjects comprised 93 males, aged 9 to 18 (mean±standard deviation age 13.8±2.6) years. In 63 of 93 (67.7%) the gynecomastia was confirmed and 28 were followed-up for a median period of three months. None of the boys showed any reduction in breast size during follow-up. There was no correlation between body mass index Z-score and breast size. Breast enlargement progressed in nine boys (32.1%). A positive correlation between estrogen to testosterone (E2/TTE) ratio and Tanner B stage (r=0.47; p=0.034) was observed. Conclusion: The E2/TTE ratio may be a helpful tool in diagnosing gynecomastia. Altered E2/TTE ratio might be responsible for a proportion of cases described previously as idiopathic. Additionally, weight loss does not imply reduction of breast size in boys. Nonetheless it should be the first step in the management of prolonged gynecomastia.
Assuntos
Desenvolvimento do Adolescente , Proliferação de Células , Desenvolvimento Infantil , Estradiol/sangue , Ginecomastia/sangue , Ginecomastia/patologia , Glândulas Mamárias Humanas/patologia , Testosterona/sangue , Adolescente , Fatores Etários , Biomarcadores/sangue , Criança , Humanos , Masculino , Fenótipo , Puberdade , Estudos RetrospectivosRESUMO
This study aimed to report a unique case of primary adrenal insufficiency that was accompanied by painful gynecomastia, which was resolved by treatment with prednisone. Enlargement of the left breast with continuous weakness and generalized nausea in a male was discovered 3 months before admission. Magnetic resonance imaging of the brain was normal 1 month before presentation. A physical examination revealed that the diameter of the left breast was 5 cm and the height was 3 cm. Laboratory investigations revealed hyponatremia, with a low serum cortisol level and an elevated prolactin level. Hyperprolactinemia was suspected because of adrenal deficiency that was directly or indirectly associated with increased prolactin levels. Thus, a diagnosis of hyperprolactinemia was confirmed. Ultrasonography of the left breast showed glandular tissue hyperplasia. In the present study, treating adrenal insufficiency with prednisone relieved both gynecomastia and hyponatremia. However, gynecomastia regression and hyponatremia resolution were observed when prednisone was stopped. Gynecomastia completely resolved by re-administering prednisone. Therefore, treating the underlying disease is essential so that prednisone can be given in a timely manner.
Assuntos
Ginecomastia/tratamento farmacológico , Prednisona/uso terapêutico , Idoso , Ginecomastia/sangue , Ginecomastia/diagnóstico por imagem , Ginecomastia/patologia , Hormônios/sangue , Humanos , Hiperplasia , Imageamento por Ressonância Magnética , Masculino , Ultrassonografia DopplerRESUMO
This study aimed to determine whether there were any differences in trace element levels between adolescent boys with gynecomastia and control boys and to determine the correlations between the levels of trace elements and body mass index (BMI) and sex hormones. The pubertal gynecomastia group comprised of 41 patients (mean age=13.2 ±0.9 years), who were admitted to Hacettepe University Ihsan Dogramaci Children's Hospital in Ankara. Control group comprised of 21 healthy male children. Analyses of trace element levels were performed atomic absorption spectrometry. The mean zinc level of control group was 101.33±16.87µg/dL and the mean zinc level of gynecomastia group was 81.36±17,43µg/dL (20% lower in gynecomastia patients, p=0.0001). However, the mean copper and manganese levels of gynecomastia patients were not statistically different than the control group. There were significant positive correlations between plasma zinc and total testosterone levels in gynecomastia group (r=0.592; p<0.05). There was a significant negative correlation between plasma zinc levels and BMI (r=-0.311; p<0.05). These results indicate that zinc deficiency might be one of the underlying factors of gynecomastia, the importance of which needs to be further elucidated.
Assuntos
Ginecomastia/sangue , Puberdade/sangue , Zinco/sangue , Adolescente , Índice de Massa Corporal , Mama/patologia , Cobre/sangue , Hormônios/sangue , Humanos , Lipídeos/sangue , Masculino , Manganês/sangue , Tamanho do Órgão , Oligoelementos/sangueAssuntos
Puberdade Tardia/diagnóstico , Puberdade Tardia/etiologia , Puberdade Precoce/diagnóstico , Puberdade Precoce/etiologia , Adolescente , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Gonadotropinas/sangue , Ginecomastia/sangue , Ginecomastia/diagnóstico , Ginecomastia/etiologia , Humanos , Hipogonadismo/sangue , Hipogonadismo/diagnóstico , Hipogonadismo/etiologia , Lactente , Recém-Nascido , Masculino , Gravidez , Puberdade Tardia/sangue , Puberdade Precoce/sangue , Valores de ReferênciaRESUMO
OBJECTIVE: Gynaecomastia is a benign proliferation of glandular tissue of the breast; however, it is an important clinical observation because it can be the first symptom of an underlying disease. Some controversy exists concerning the clinical importance of an in-depth investigation of men who develop gynaecomastia. We hypothesise that a thorough work-up is required in adult men with gynaecomastia. DESIGN: All adult men (n = 818) referred to a secondary level andrological department at Rigshospitalet in Copenhagen, Denmark during a four-year period (2008-2011) under the diagnosis of gynaecomastia (ICD-10: N62) were included. METHODS: Thirty-two men who did not have gynaecomastia when examined were excluded; leaving 786 men for final analyses. They underwent an andrological examination, ultrasound of the testicles and analysis of endogenous serum hormones levels. RESULTS: In 43% of men with adult onset of gynaecomastia (≥18 years) an underlying, and often treatable, cause could be detected. In men younger at onset an underlying cause for gynaecomastia could be detected in merely 7.7%. The study is limited by the fact that we did not have access to investigate men who were referred directly by their GP to private clinics for plastic surgery or who sought cosmetic correction without consulting their GP first. CONCLUSIONS: Our study demonstrates the importance of a thorough examination and provides a comprehensible examination strategy to disclose the underlying pathology leading to the development of gynaecomastia in adulthood.
Assuntos
Ginecomastia/sangue , Ginecomastia/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Dinamarca/epidemiologia , Ginecomastia/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Testosterona/sangue , Adulto JovemRESUMO
OBJECTIVE: Aromatase, or CYP19A1, is a type II cytochrome CYP450 enzyme that catalyzes the conversion of C19 androgens to C18 estrogens. Its crucial role in both female and male physiology has been deduced from human and animal studies using aromatase inhibitors, genetically altered mice, and patients with aromatase deficiency. The latter is an extremely rare disorder. Its diagnosis is particularly difficult in males, who go through puberty normally and therefore usually present as adults with elevated testosterone, bone abnormalities (e.g., delayed bone age and low bone mass), and metabolic syndrome. In this report, we describe a new case of a male patient with aromatase deficiency harboring a known mutation who presented with less severe clinical and biochemical features. CASE REPORT: The patient presented with low bone mass and delayed bone age after a finger fracture at age 25years. FSH, LH and testosterone levels were normal, but estradiol and estrone levels were absent or barely detectable, raising suspicion for aromatase deficiency. A homozygous c.628G>A mutation in exon 5 was confirmed by direct sequencing. Unlike previously reported cases of aromatase deficiency, he did not display biochemical features of insulin resistance, dyslipidemia, or overweight/obese status. Therapy with estradiol led to the closure of growth plates and a dramatic increase in bone mass. CONCLUSIONS: Here we explore genotype/phenotype associations of this new case compared to cases reported previously. We conclude that the specific nature of mutation c.628G>A, which can potentially result in several different forms of the aromatase enzyme, may lend an explanation to the variable phenotypes associated with this particular genotype.
Assuntos
Transtornos 46, XX do Desenvolvimento Sexual/patologia , Aromatase/deficiência , Ginecomastia/patologia , Infertilidade Masculina/patologia , Erros Inatos do Metabolismo/patologia , Transtornos 46, XX do Desenvolvimento Sexual/sangue , Transtornos 46, XX do Desenvolvimento Sexual/tratamento farmacológico , Adolescente , Adulto , Determinação da Idade pelo Esqueleto , Aromatase/sangue , Estradiol/sangue , Estradiol/farmacologia , Estradiol/uso terapêutico , Fraturas Ósseas/diagnóstico por imagem , Fraturas Ósseas/tratamento farmacológico , Fraturas Ósseas/patologia , Ginecomastia/sangue , Ginecomastia/tratamento farmacológico , Humanos , Infertilidade Masculina/sangue , Infertilidade Masculina/tratamento farmacológico , Masculino , Erros Inatos do Metabolismo/sangue , Erros Inatos do Metabolismo/tratamento farmacológico , Testosterona/sangue , Fatores de TempoRESUMO
BACKGROUND: Gynecomastia is defined as benign proliferation of male breast glandular tissue. To date, the pathophysiology of adolescent gynecomastia (AG) remains unclear. Kisspeptin is a polypeptide that plays an important role in the regulation of the hypothalamic-pituitary-gonadal hormonal axis. In this study, we investigated whether there is a relationship between kisspeptin and AG. MATERIALS AND METHODS: This study included 40 males between 9 and 18 years of age diagnosed with gynecomastia. The control group consisted of 30 young healthy males in the same age range. The participants were evaluated with respect to anthropometric measurements (age, height, body weight, body mass index, breast and pubic stages and testicular volume). The levels of kisspeptin, follicle-stimulating hormone, luteinizing hormone, estradiol (E2), testosterone (T), and ratio of E2 to T were measured in both groups. RESULTS: The mean age was 13.8 years. There were no differences between the groups in terms of anthropometric parameters, plasma gonadotropin levels, estrogen levels, and E2/T (P > 0.05). Plasma kisspeptin (0.77 and 0.54 ng/mL, P < 0.05) and T (253.9 ng/dL and 117.9 ng/dL) levels were significantly higher in the AG group than in the control group (P < 0.001). CONCLUSION: Kisspeptin levels are an important factor in AG.
Assuntos
Ginecomastia/sangue , Kisspeptinas/sangue , Adolescente , Estudos de Casos e Controles , Criança , Ginecomastia/etiologia , Humanos , Masculino , Fatores de RiscoRESUMO
OBJECTIVES: To compare sexual function and hormone profile in male patients with gynecomastia with matched controls. MATERIALS-METHODS: Forty-seven male subjects with gynecomastia and thirty healthy controls were enrolled in this study. Serum free T3, free T4, TSH, FSH, prolactin, estradiol, total testosterone, free testosterone, DHEA-SO4, LH and total PSA were measured in the patients and controls. Sexual function of the patients and controls were evaluated using International Index of Erectile Function (IIEF). The hormone values and IIEF scores of the patients were statistically compared with the controls'. RESULTS: The mean of age, body mass index, right and left testicular volume in the patient and control group were similar. The mean FSH and free T3 values of the patients were significantly lower than the controls (p = 0.007 and p = 0.03, respectively). The mean of the other hormone values in the both groups were found to be statistically similar (p > 0.05). The mean ±SD of total IIEF scores in the patient and control group were 60.14 ± 8.78 and 65.24 ± 5.52, respectively (p = 0.007). Although the mean IIEF-erectile function, orgasmic function and intercourse satisfaction scores in the patient group were significantly lower than the control group (p < 0.001, p = 0.004 and p = 0.001, respectively), the mean IIEF-desire score of the patients was significantly higher than the controls (p = 0.002). CONCLUSION: We found that the hormone profiles (except FSH and free T3) of the patients with gynecomastia were similar with the controls. However, gynecomastia adversely affected male sexual function.
Assuntos
Disfunção Erétil/epidemiologia , Ginecomastia/epidemiologia , Saúde Reprodutiva , Disfunções Sexuais Psicogênicas/epidemiologia , Adolescente , Adulto , Estudos de Casos e Controles , Sulfato de Desidroepiandrosterona/sangue , Disfunção Erétil/sangue , Estradiol/sangue , Hormônio Foliculoestimulante/sangue , Ginecomastia/sangue , Humanos , Calicreínas/sangue , Hormônio Luteinizante/sangue , Masculino , Orgasmo , Ereção Peniana , Prolactina/sangue , Antígeno Prostático Específico/sangue , Disfunções Sexuais Psicogênicas/sangue , Testosterona/sangue , Tireotropina/sangue , Tiroxina/sangue , Tri-Iodotironina/sangue , Adulto JovemRESUMO
CONTEXT: Physiological gynecomastia is common and affects a large proportion of otherwise healthy adolescent boys. It is thought to be caused by an imbalance between estrogen and testosterone, although this is rarely evident in analyses of serum. OBJECTIVE: This study aimed to describe the frequency of physiological gynecomastia and to determine possible etiological factors (eg, auxology and serum hormone levels) in a longitudinal setup. DESIGN, SETTINGS, AND PARTICIPANTS: A prospective cohort study of 106 healthy Danish boys (5.8-16.4 years) participated in the longitudinal part of the COPENHAGEN Puberty Study. The boys were examined every 6 months during an 8-year follow-up. Median number of examinations was 10 (2-15). MAIN OUTCOME MEASUREMENTS: Blood samples were analyzed for FSH, LH, testosterone, estradiol, SHBG, inhibin B, anti-Müllerian hormone, IGF-1, and IGF binding protein-3 by immunoassays. Auxological parameters, pubertal development, and the presence of gynecomastia were evaluated at each visit. RESULTS: Fifty-two of 106 boys (49%) developed gynecomastia, of which 10 (19%) presented with intermittent gynecomastia. Boys with physiological gynecomastia reached peak height velocity at a significantly younger age than boys who did not develop gynecomastia (13.5 versus 13.9 years, P = .027), and they had significantly higher serum levels of IGF-1 (P = .000), estradiol (P = .013), free testosterone (P < .001), and FSH (P = .030) during pubertal transition. However, no differences in serum LH or in the estradiol to testosterone ratio were found. CONCLUSIONS: Gynecomastia is frequent in pubertal boys. Increased IGF-1 levels and pubertal growth appear to be associated, whereas changes in estrogen to testosterone ratio seem negligible.
Assuntos
Estatura/fisiologia , Estradiol/sangue , Ginecomastia/fisiopatologia , Fator de Crescimento Insulin-Like I/metabolismo , Testosterona/sangue , Adolescente , Hormônio Antimülleriano/sangue , Criança , Pré-Escolar , Hormônio Foliculoestimulante/sangue , Ginecomastia/sangue , Humanos , Inibinas/sangue , Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue , Estudos Longitudinais , Hormônio Luteinizante/sangue , Masculino , Estudos Prospectivos , Puberdade/sangue , Puberdade/fisiologia , Globulina de Ligação a Hormônio Sexual/metabolismoRESUMO
A 74-year-old man presented to the outpatient clinic with painful gynaecomastia. A detailed physical examination to sort out possible causes of the gynaecomastia, including intracranial tumour, liver cirrhosis, hyperthyroidism, and adrenal and testicular tumour, was negative. No offending agent was found in his medication list. A CT scan of the head and ultrasound of the scrotum did not show any mass lesion. His serum ß-human chorionic gonadotropin (ß-hCG) and oestradiol levels were elevated. A CT scan of the abdomen and pelvis revealed bladder wall thickening with soft tissue mass. A cystoscopic biopsy confirmed transitional cell carcinoma with muscle invasion. The patient was started on chemotherapy but responded poorly. This case report describes the ß-hCG and oestradiol-secreting transitional cell carcinoma of the bladder presenting as gynaecomastia in an older man.
Assuntos
Mama/patologia , Carcinoma de Células de Transição/diagnóstico , Gonadotropina Coriônica Humana Subunidade beta/sangue , Estradiol/sangue , Ginecomastia/diagnóstico , Neoplasias da Bexiga Urinária/diagnóstico , Bexiga Urinária/patologia , Idoso , Carcinoma de Células de Transição/sangue , Carcinoma de Células de Transição/complicações , Gonadotropina Coriônica Humana Subunidade beta/metabolismo , Estradiol/metabolismo , Ginecomastia/sangue , Ginecomastia/etiologia , Humanos , Masculino , Tomografia Computadorizada por Raios X , Neoplasias da Bexiga Urinária/sangue , Neoplasias da Bexiga Urinária/complicaçõesRESUMO
AIM: The G protein-coupled receptor, GPR30, which is a third estrogen receptor, has been shown to mediate estrogenic effects on the essential features of human breast cancer cells. The aim of this study was to evaluate the association between GPR30 single nucleotide polymorphisms and gynecomastia in males. METHODS: This study included 109 male adolescents with gynecomastia and 104 controls. Follicle stimulating hormone, luteinizing hormone, total testosterone, estradiol (E2), dehydroepiandrosterone sulfate (DHEAS), and prolactin levels were measured. DNA was extracted from whole blood using a GeneJET Genomic DNA purification kit. The genotypes of the GPR30 gene (rs3808350, rs3808351 and rs11544331) were studied using a tetra-primer ARMS (amplification refractory mutation system) PCR approach. RESULTS: The median E2 (11.80 vs. 16.86 IU/l, p < 0.001) and DHEAS levels (116.8 vs. 146.5 µg/dl, p = 0.044) were higher in the gynecomastia group. The G allele of rs3808350 and the A allele of rs3808351 were frequently observed in patients with gynecomastia. Gynecomastia was more common in patients with the GG genotype of rs3808350 and in patients with the AA genotype of rs3808351. CONCLUSIONS: Our results suggest that increased E2 levels, the G allele of rs3808350 and the A allele of rs3808351 might explain why certain adolescents are affected by gynecomastia.
Assuntos
Alelos , Frequência do Gene , Ginecomastia/genética , Polimorfismo de Nucleotídeo Único , Receptores de Estrogênio/genética , Receptores Acoplados a Proteínas G/genética , Adolescente , Adulto , Ginecomastia/sangue , Hormônios/sangue , Humanos , Masculino , Receptores de Estrogênio/metabolismo , Receptores Acoplados a Proteínas G/metabolismoAssuntos
Ginecomastia/genética , Infertilidade Masculina/genética , Mutação/genética , Receptores Androgênicos/genética , Adulto , Sequência de Aminoácidos , Éxons/genética , Ginecomastia/sangue , Ginecomastia/diagnóstico , Humanos , Infertilidade Masculina/sangue , Infertilidade Masculina/diagnóstico , Masculino , Dados de Sequência Molecular , Receptores Androgênicos/análise , Testosterona/sangueRESUMO
BACKGROUND: Antipsychotic medications, particularly second-generation antipsychotics, are increasingly being used to alleviate the symptoms of schizophrenia and other severe mental disorders in the pediatric population. While evidence-based approaches examining efficacy and safety outcomes have been reported, no review has evaluated prolactin-based adverse events for antipsychotic treatments in schizophrenia and schizophrenia spectrum disorders. METHODS/DESIGN: Searches involving MEDLINE, EMBASE, CENTRAL, PsycINFO, and clinical trial registries (ClinicalTrials.gov, Drug Industry Document Archive [DIDA], International Clinical Trials Registry Platform [ICTRP]) will be used to identify relevant studies. Two reviewers will independently screen abstracts and relevant full-text articles of the papers identified by the initial search according to the prospectively defined eligibility criteria. Data extraction will be conducted in duplicate independently. Pairwise random effects meta-analyses and network meta-analyses will be conducted on individual drug and class effects where appropriate. DISCUSSION: This systematic review will evaluate prolactin-based adverse events of first- and second-generation antipsychotics in the pediatric population with schizophrenia and schizophrenia spectrum disorders. It will also seek to strengthen the evidence base of the safety of antipsychotics by incorporating both randomized controlled trials and observational studies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42014009506.
Assuntos
Antipsicóticos/efeitos adversos , Prolactina/sangue , Projetos de Pesquisa , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Adolescente , Criança , Pré-Escolar , Feminino , Galactorreia/sangue , Galactorreia/induzido quimicamente , Ginecomastia/sangue , Ginecomastia/induzido quimicamente , Humanos , Masculino , Distúrbios Menstruais/sangue , Distúrbios Menstruais/induzido quimicamente , Disfunções Sexuais Fisiológicas/sangue , Disfunções Sexuais Fisiológicas/induzido quimicamente , Revisões Sistemáticas como AssuntoRESUMO
OBJECTIVE: Pubertal gynaecomastia is a frequent phenomenon occurring in 20-40% of otherwise healthy adolescent boys. Little is known about the aetiology of pubertal gynaecomastia. Markedly elevated thyroid hormone levels in adults with hyperthyroidism are associated with gynaecomastia. DESIGN: A cross-sectional examination of 444 healthy boys with and without pubertal gynaecomastia. METHODS: We evaluated TSH, triiodothyronine (T3), thyroxine (T4), free T4 and free T3 in a cohort of healthy boys with and without pubertal gynaecomastia. RESULTS: Boys with gynaecomastia had significantly higher serum free T3, even after correction for age, BMI and pubertal stage. After inclusion of IGF1 in the model the differences disappeared. TSH, T4, free T4 and T3 did not differ between the groups. CONCLUSIONS: We speculate that the GH/IGF1 axis and thyroid hormones interact and influence the development of pubertal gynaecomastia.
Assuntos
Ginecomastia/sangue , Tri-Iodotironina/sangue , Adolescente , Estudos Transversais , Humanos , Fator de Crescimento Insulin-Like I/metabolismo , Masculino , Puberdade/fisiologia , Tireotropina/sangue , Tiroxina/sangueRESUMO
PURPOSE: To analyze possible relationships between gynecomastia and clinical and biochemical parameters in a large cohort of subjects with sexual dysfunction (SD). METHODS: A consecutive series of 4,023 men attending our Outpatient Clinic for SD was retrospectively studied. RESULTS: After excluding Klinefelter's syndrome patients, the prevalence of gynecomastia was 3.1 %. Subjects with gynecomastia had significantly lower testosterone (T) levels; the association retained statistical significance after adjusting for age and life-style. However, only 33.3 % of subjects with gynecomastia were hypogonadal. Gynecomastia was associated with delayed puberty, history of testicular or hepatic diseases, as well as cannabis abuse. Patients with gynecomastia more frequently reported sexual complaints, such as severe erectile dysfunction [odds ratio (OR) = 2.19 (1.26-3.86), p = 0.006], lower sexual desire and intercourse frequency [OR = 1.23 (1.06-1.58) and OR = 1.84 (1.22-2.78), respectively; both p < 0.05], orgasm difficulties [OR = 0.49 (0.28-0.83), p = 0.008], delayed ejaculation and lower ejaculate volume [OR = 1.89 (1.10-3.26) and OR = 1.51 (1.23-1.86), respectively; both p < 0.05]. Gynecomastia was also positively associated with severe obesity, lower testis volume and LH, and negatively with prostate-specific antigen levels. The further adjustment for T did not affect these results, except for obesity. After introducing body mass index as a further covariate, all the associations retained statistical significance, except for delayed ejaculation and ANDROTEST score. When considering gynecomastia severity, we found a step-wise, T-independent, decrease and increase of testis volume and LH, respectively. Gynecomastia was also associated with the use of several drugs in almost 40 % of our patients. CONCLUSION: Gynecomastia is a rare condition in subjects with SD, and could indicate a testosterone deficiency that deserves further investigation.